Openfund

CORDIS · ONCOSCREEN

A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways

Код
ONCOSCREEN
Програма
HORIZON
Процедура
HORIZON-MISS-2021-CANCER-02-01
Статус
SIGNED
Период
01.01.2023 – 31.12.2026
Обща стойност (целият консорциум)12 972 076 €
Принос на ЕС (целият консорциум)12 972 076 €
Принос на ЕС за българските участници511 625 €

Официални данни · CORDIS · синхронизирано 17.10.2026 10:16 · официален запис

Участници

ОрганизацииРоляДържаваБезвъзмездна помощ
EXUS SOFTWARE MONOPROSOPI ETAIRIA PERIORISMENIS EVTHINISкоординаторEL1 006 628 €
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGYучастникIL909 450 €
UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZучастникDE777 500 €
MEDIZINISCHE UNIVERSITAT GRAZучастникAT695 375 €
FIRALISучастникFR691 500 €
EREVNITIKO PANEPISTIMIAKO INSTITOUTO SYSTIMATON EPIKOINONION KAI YPOLOGISTONучастникEL623 250 €
ROSENBAUM CONSULTINGучастникBG511 625 €
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXISучастникEL495 750 €
UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEINучастникDE441 830 €
INSTITUTO PORTUGUES DE ONCOLOGIA DO PORTO FRANCISCO GENTIL, EPEучастникPT439 750 €
LIETUVOS SVEIKATOS MOKSLU UNIVERSITETASучастникLT420 000 €
VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK N.V.участникBE408 310 €
TILBURG UNIVERSITY- UNIVERSITEIT VAN TILBURGучастникNL351 500 €
UNIVERSIDADE DO MINHOучастникPT329 975 €
SCIENTIFIC ACADEMY FOR SERVICE TECHNOLOGY EVучастникDE329 350 €
AINIGMA TECHNOLOGIESучастникBE298 750 €
INNOVATION SPRINTучастникBE278 250 €
INSTITUTUL ONCOLOGIC PROF. DR. ALEXANDRU TRESTIOREANU BUCURESTIучастникRO268 750 €
KONNEKT ABLE TECHNOLOGIES LIMITEDучастникIE265 000 €
TIMELEXучастникBE247 188 €
UNIVERSIDAD DE LA RIOJAучастникES240 000 €
CATALINK LIMITEDучастникCY239 875 €
EY ADVISORY SPAучастникIT228 125 €
GIE AXAучастникFR220 625 €
CARR COMMUNICATIONS LIMITEDучастникIE211 250 €
YPOURGEIO YGEIASучастникEL207 500 €
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASучастникES196 625 €
UNIVERSITE MARIE ET LOUIS PASTEURучастникFR182 977 €
BEIA CONSULT INTERNATIONAL SRLучастникRO182 250 €
GENIKO NOSOKOMEIO ELENA VENIZELOU -ALEXANDRAучастникEL178 125 €
PAGALBOS ONKOLOGINIAMS LIGONIAMS ASOCIACIJAучастникLT143 750 €
LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJAучастникLT130 184 €
EUROPACOLON PORTUGAL- ASSOCIACAO DE LUTA CONTRA O CANCRO DO INTESTINOучастникPT115 000 €
FUNDATIA YOUTH CANCER EUROPEучастникRO105 750 €
EUROPAISCHE VEREINIGUNG DER GASTROINTESTINALEN ONKOLOGIE(EUROPEAN SOCIETY OF DIGESTIVE ONCOLOGY - ESDO)участникAT99 875 €
LOUWEN ROGIERучастникNL99 688 €
VOOGD SANNEучастникNL99 688 €
ELLINIKI ETAIREIA OGKOLOGIAS PEPTIKOUучастникEL92 625 €
FAKULTNA NEMOCNICA S POLIKLINIKOU F.D. ROOSEVELTA BANSKA BYSTRICAучастникSK86 618 €
Delta Health Care S.R.LучастникRO68 750 €
MEDIZINISCHE UNIVERSITAT INNSBRUCKучастникAT47 068 €
ASSOCIATION GERCORучастникFR6 000 €
UNIVERSITAET zu LUEBECKтрета странаDE0 €

Описание

With Colorectal Cancer (CRC) being accountable for 12.4% of all deaths due to cancer, and with only 14% of EU citizens participating in screening programmes, there is an urgent need for accurate, non-invasive, cost-effective screening tests based on novel technologies and an increased awareness on the disease and its detection. Furthermore, personalized approaches for screening are needed, to consider genetic and other socioeconomic variables and environmental stressors that lead to different onsets of the disease. ONCOSCREEN responds to these challenges by developing a risk-based, population-level stratification methodology for CRC, to account for genetic prevalence, socio-economic status, and other factors. It complements this methodology by a) developing a set of novel, practical, and low-cost screening technologies with high sensitivity and specificity, b) leveraging AI to improve existing methodologies for CRC screening, allowing for the early detection of polyps and provision of a personalized risk status stratification, and c) providing a mobile app for self-monitoring and CRC awareness raising. Furthermore, ONCOSCREEN develops an Intelligent Analytics dashboard for policy makers facilitating effective policy making at regional and national levels. Through a multi-level campaign, the above-mentioned solutions are tested and validated. For the clinical solutions specifically, a clinical validation study has been planned with the participation of 4100 enrolled patients/citizens. To ensure the adoption of the developed solutions by the healthcare systems, their cost-effectiveness and financial viability will be assessed. The 48-months duration project will be implemented by a multidisciplinary consortium comprising of 38 partners, including technical solutions providers, hospitals, Ministries of Health as policy makers, legal and ethics experts, Insurance companies, involving actively end-users/citizens in all phases of implementation through targeted workshops. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening.

Официални данни · CORDIS · синхронизирано 17.10.2026 10:16 · официален запис · Лиценз: © European Union, CC BY 4.0 (Commission reuse policy).